Pharmacological treatment of social anxiety disorder.

Modern trends in pharmacopsychiatry Pub Date : 2013-01-01 Epub Date: 2013-09-20 DOI:10.1159/000351960
Vasilios G Masdrakis, Darko Turic, David S Baldwin
{"title":"Pharmacological treatment of social anxiety disorder.","authors":"Vasilios G Masdrakis,&nbsp;Darko Turic,&nbsp;David S Baldwin","doi":"10.1159/000351960","DOIUrl":null,"url":null,"abstract":"<p><p>Social anxiety disorder (social phobia) is a common and typically long-standing medical condition, characterized by an excessive fear of being observed or evaluated negatively in social or performance situations. Efficacious interventions in acute treatment include cognitive behavioural therapy and a range of medications including many antidepressants, some benzodiazepines and anticonvulsants, and the antipsychotic olanzapine. Most studies report no significant differences in overall efficacy or tolerability between active compounds. Responders to previous acute treatment benefit from continuing active medication for 6 months. Evidence of a dose-response relationship with antidepressant drugs is inconsistent, though only higher doses of pregabalin are efficacious. Switching between treatments with proven efficacy may be helpful. Augmentation of a selective serotonin reuptake inhibitor with buspirone or clonazepam can be beneficial. It is unlikely that combining pharmacotherapy with psychotherapy results in greater overall efficacy compared to either treatment given alone. Proof-of-concept and other preliminary studies suggest the efficacy of psychotherapy can be enhanced through prior administration of D-cycloserine, cannabidiol, or oxytocin. </p>","PeriodicalId":74212,"journal":{"name":"Modern trends in pharmacopsychiatry","volume":"29 ","pages":"144-53"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000351960","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern trends in pharmacopsychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000351960","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/9/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

Social anxiety disorder (social phobia) is a common and typically long-standing medical condition, characterized by an excessive fear of being observed or evaluated negatively in social or performance situations. Efficacious interventions in acute treatment include cognitive behavioural therapy and a range of medications including many antidepressants, some benzodiazepines and anticonvulsants, and the antipsychotic olanzapine. Most studies report no significant differences in overall efficacy or tolerability between active compounds. Responders to previous acute treatment benefit from continuing active medication for 6 months. Evidence of a dose-response relationship with antidepressant drugs is inconsistent, though only higher doses of pregabalin are efficacious. Switching between treatments with proven efficacy may be helpful. Augmentation of a selective serotonin reuptake inhibitor with buspirone or clonazepam can be beneficial. It is unlikely that combining pharmacotherapy with psychotherapy results in greater overall efficacy compared to either treatment given alone. Proof-of-concept and other preliminary studies suggest the efficacy of psychotherapy can be enhanced through prior administration of D-cycloserine, cannabidiol, or oxytocin.

社交焦虑障碍的药物治疗。
社交焦虑障碍(社交恐惧症)是一种常见且典型的长期医疗状况,其特征是过度害怕在社交或表演场合被消极地观察或评价。在急性治疗中,有效的干预措施包括认知行为疗法和一系列药物,包括许多抗抑郁药、一些苯二氮卓类药物和抗惊厥药,以及抗精神病药奥氮平。大多数研究报告在活性化合物之间的总体疗效或耐受性没有显着差异。对先前急性治疗有反应者可继续积极用药6个月。抗抑郁药物的剂量-反应关系的证据是不一致的,尽管只有高剂量的普瑞巴林有效。在已证实有效的治疗方法之间转换可能会有所帮助。丁螺环酮或氯硝西泮增加选择性血清素再摄取抑制剂可能是有益的。与单独给予任何一种治疗相比,药物治疗与心理治疗相结合不太可能产生更大的总体疗效。概念验证和其他初步研究表明,心理治疗的效果可以通过事先服用d -环丝氨酸、大麻二酚或催产素来增强。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信